For more than 127 years, Lilly has been a global health innovator. We are pleased to continue this tradition by announcing plans to invest an additional $50 million in an innovative, global partnership to fight Multi-Drug Resistant Tuberculosis (MDR-TB). This new commitment furthers Lilly's support of a pioneering initiative started in 2003, and brings the total Lilly investment to $120 million. The funding supports a multi-pronged strategy to increase the supply and availability of effective drugs for treating the complex and life-threatening disease; training for front-line health care personnel; and efforts to focus global resources on prevention, diagnosis, and treatment of MDR-TB.
Media Kit Materials
- MDR-TB partnership press release - March 22, 2007 (PDF)
- MDR-TB Lilly partnership slides (PDF)
- Lilly MDR-TB ad - March 22, 2007 (PDF)
- MDR-TB brochure (PDF)
- MDR-TB partnership fact sheet (PDF)
- MDR-TB disease fact sheet (PDF)
- MDR-TB partnership frequently asked questions (FAQs) (PDF)
- MDR-TB global partners local action map
- MDR-TB drug supply chain map
Important Note: You must have Acrobat Reader version 4.0 or higher installed to view these files. If you have an earlier version installed, an update is available from the Adobe Acrobat Reader download site.
